HCV-Induced Hepatocellular Carcinoma and Its Management Strategies

Abstract

Hepatocellular carcinoma is the term used to describe liver cancer (HCC). Liver cancer is presently the fifth most prevalent malignancy in males and the seventh most prevalent cancer in women, with fatality rates increasing over the last 20 years. The intricacy of HCV-induced hepatocarcinogenesis is mostly due to pathway alterations that are either immune-mediated as a result of ongoing inflammation or principally driven by infectious causes. Host genetic diversity may be a risk factor for HCC according to emerging data. The initial course of therapy when a patient qualifies for a liver transplant is surgical removal or transplantation. Since it was first used to treat HCC in 2007, sorafenib has been an important part of systemic treatment that has worked well. It wasn't until 2017 that some significant strides in the creation of systemic methods were achieved. Despite this, the past several years have seen significant progress in the creation of novel treatments thanks to many clinical studies in HCC and extensive fundamental research. Recent advancements have been made in both newly developed immunotherapy methods and well-established systemic treatment approaches. The American (FDA) licensed a variety of medications between 2017 and 2020 for the treatment of HCC. These drugs include bevacizumab plus atezolizumab, regorafenib, levatinib, cabozantinib, and ramucirumab, as well as immune checkpoint antagonist like nivolumab and pembrolizumab.in this paper we review of HCV induced HCC and its therapeutic approaches.